Stock Ratings / Health Care / PRFX / options

DCOY (31) HCWB (23) APVO (35) JUNS (29) ⌘ Pro Terminal →

PRF Technologies Ltd. (PRFX) Options Positioning, Max Pain & Unusual Sweeps

$0.73 -2.68% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.73

PRF Technologies Ltd. (PRFX) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $2.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PRFX Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PRFX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, PRF Technologies Ltd. (NASDAQ: PRFX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $0.73 (-2.68% 1D, market cap $2.6M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, PRFX ranks #708 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PRFX compare to DCOY and HCWB in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PRFX carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of -30.0%, and ROIC of -35.0%. By comparison, DCOY (Decoy Therapeutics Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $2.6M) and HCWB (HCW Biologics Inc.) posts a E grade (23/100 RQD, P/E N/A, ROIC -35.0%, cap $2.5M). Among the 5-stock peer group, PRFX leads on earnings multiple (N/A) while PRFX leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PRFX?

▼

Per PRFX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001801834), PRF Technologies Ltd. generated $17.0K in revenue, -$5.0M in net income, and -$4.0M in free cash flow against $12.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.73 (-0.67%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.9% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-11% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PRFX)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (33/100 Composite)

🔍 WHY PRFX SCORES 33/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+8/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 0% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (24% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$0.82-11% Next Q

Q2 (-2Q)

Grade E$0.73+4.1% Next Q

Q3 (-1Q)

Grade E$0.76-3.9% Next Q

Current

Grade E$0.73-8.9% Hist 90D α

Trajectory: D (41) → E (33)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PRFX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PRFX currently carries a cautious 33/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.88) and Max Pain ($0.77) forces dealer call-delta covering toward $8.35.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PRFX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “PRFX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 33%NO 67%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (PRFX)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for PRFX.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PRFX)

✓Walkthrough of PRFX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PRFX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -62.94%🛡️ HOLDING TREND SUPPORT

2026-11-03O $0.75H $0.75L $0.73C $0.73VOL 58.6K

RES: $1.25SUP: $0.64SMA50: $0.88SMA200: $1.79

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PRFX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PRFX Butterfly Map → + Track PRFX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PRFX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PRFX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PRFX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PRFX)

Health Care Rank #708 of 1016 ⚔️ DCOY vs PRFX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PRFX vs. DCOY, HCWB, APVO, JUNS)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, PRF Technologies Ltd. (PRFX) ranks #708 by composite RQD confidence (33/100, grade E) and #982 by equity capitalization ($2.6M). Within this direct 5-issuer industry benchmark cohort, PRFX leads on earnings valuation at N/A trailing P/E, while PRFX leads on capital efficiency and profitability with -35.0% ROIC and -30.0% gross margin. APVO currently holds the highest overall quantitative score in the immediate peer group at 35/100 (D-) compared with PRFX at 33/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PRFX ACTIVE PRF Technologies Ltd.	E	33/100	—	-30.0%	-35.0%	-2.68%	$2.6M	Benchmark Subject
DCOY Decoy Therapeutics Inc.	E	31/100	—	—	-35.0%	-13.01%	$2.6M	/dcoy-vs-prfx →
HCWB HCW Biologics Inc.	E	23/100	—	20.0%	-35.0%	-6.78%	$2.5M	/hcwb-vs-prfx →
APVO Aptevo Therapeutics Inc.	D-	35/100	—	—	-35.0%	-1.47%	$2.4M	/apvo-vs-prfx →
JUNS Jupiter Neurosciences Inc.	E	29/100	—	80.6%	-35.0%	-13.50%	$2.7M	/juns-vs-prfx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001801834

In its most recent audited fiscal period (FY2025, filed 2025-12-31), PRF Technologies Ltd. (PRFX) reported GAAP revenue of $17.0K (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$5.0M, operating cash flow of -$4.0M, and free cash flow of -$4.0M (+68.7% YoY). On the balance sheet, PRFX closed FY2025 with $12.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$17.0K	-$5.0M	-$4.0M	-$4.0M	$12.0M	—
FY2024 (FY)	2024-12-31	$0	-$14.6M	-$12.6M	-$12.6M	$4.5M	—
FY2023 (FY)	2023-12-31	$0	-$9.3M	-$6.7M	-$6.7M	—	—

3. PRFX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PRFX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does PRFX compare to DCOY and HCWB in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for PRFX?

Where is PRFX trading relative to its 50-day, 200-day, and 52-week technical levels?

PRFX last traded at $0.73 (-2.68% on volume of 58,596 shares), positioning the stock -17.05% below its 50-day simple moving average ($0.88) and -59.22% below its 200-day simple moving average ($1.79). Across its 52-week range of $0.69 to $7.95, PRFX sits at the 0.6% percentile with a 14-day RSI of 37.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.82).

PRFX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is PRFX's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for PRFX.

Direct Sub-Reports: PRFX RQD Cockpit PRFX 12M Forecast PRFX Earnings & Move PRFX Dividends & DRIP PRFX Insiders & 13F PRFX Whale Options PRFX Profit Sankey PRFX News & Why

ROARABLE RATING BRIEF • RQD 33/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

PRFX — PRF Technologies Ltd.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:54:25Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, PRFX scores 34 out of 100 for a letter grade of E, with the verdict label "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are scored as follows: Fundamental Cash Engine 8/20 (ROIC -35%; FCF yield 0%), Whale 13F Flow 6/20 (institutional accumulation and options positioning), Insider Conviction 3/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit 9/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet 8/20 (Altman Z 2.5; Piotroski F 3/9; Debt/Equity 0.5). For a prospective investor, the lowest-scoring pillars point to the core issue: the cash engine is weak on the reported ROIC and FCF yield, and insider conviction is the weakest signal in the rating. The balance-sheet and macro pillars are mid-range rather than strong, so the rating does not offer an offsetting strength. The upside case would need to rest on catalysts outside the scored fundamentals, while the valuation tradeoff is that the stock has no reported earnings multiples to anchor a price against.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$-5.1M	$-5.0M	N/A	$-4.0M	$3.1M	N/A
FY 2024	$0.0M	$-14.7M	$-14.6M	N/A	$-12.6M	$4.3M	N/A
FY 2023	$0.0M	$-9.6M	$-9.3M	N/A	$-6.7M	N/A	N/A

Per the SEC financials, the company reported operating losses in each period shown, with net margin at -60% and operating margin at -60% and gross margin at -30% per the market data. ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 3 of 9, and Debt/Equity is 0.5. Cash declined from $4.3M in FY 2024 to $3.1M in FY 2025 per the SEC financials, while FCF remained negative in every reported period.

Recent Catalysts & News Wire Analysis

Per the recent news feed, the most substantive headlines reference an $11 million cash position, Phase 2 plans for the OcuRing™-K trial, and a GridFeed™ AI data center power strategy, reported across TradingView, Yahoo Finance UK, The Globe and Mail, Moomoo, Investing.com India, and Benzinga. The shareholder letter is described as highlighting these items. The news feed carries no quantified results or timelines beyond the headlines. Risk watch items per the data: the $11 million cash figure in headlines does not reconcile to the FY 2025 cash of $3.1M in the SEC financials, and the Phase 2 and GridFeed strategies have no reported revenue. The Butterfly Supply-Chain Graph reports no supply-chain links and no proprietary signals.

Open Questions

Where does the $11 million cash figure cited in headlines come from, given FY 2025 cash is reported as $3.1M?
What is the company's revenue source, since reported revenue is $0.0M across all periods?
What is the timeline and funding requirement for the Phase 2 OcuRing™-K trial and the GridFeed™ strategy?
What is the source of the insider and institutional flow behind the RQD pillar scores, given holder data is unavailable?
Does the company's negative free cash flow in each period imply a financing need, and how would any financing be structured?

PRFX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for PRF Technologies Ltd. (PRFX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PRFX Debate Forum (3) ↓

🟡 MARKET WIRE TradingView • 16h ago

PRF Technologies Ltd. Estimates – NASDAQ:PRFX

TradingView report covering PRF Technologies Ltd. (PRFX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance UK • 19h ago

PRF Technologies Ltd. (PRFX) Seasonal returns chart

Yahoo Finance UK report covering PRF Technologies Ltd. (PRFX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE The Globe and Mail • 22h ago

PRF Technologies Highlights $11 Million Cash, Phase 2 OcuRing™-K Trial Plans and GridFeed AI Data Center Strategy

The Globe and Mail report covering PRF Technologies Ltd. (PRFX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Moomoo • 1d ago

Press Release: PRF Technologies Issues Letter to Shareholders Highlighting $11.0 Million Cash Position, Entering Phase 2 Trial of OcuRing(TM)-K and GridFeed(TM) Opportunity in AI Data Center Power

Moomoo report covering PRF Technologies Ltd. (PRFX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com India • 1d ago

PRF Technologies reports $11M cash, plans phase 2 trial By Investing.com

Investing.com India report covering PRF Technologies Ltd. (PRFX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 1d ago

12 Health Care Stocks Moving In Friday's After-Market Session

Benzinga report covering PRF Technologies Ltd. (PRFX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE GlobeNewswire • 1d ago

PRF Technologies Issues Letter to Shareholders Highlighting $11.0 Million Cash Position, Entering Phase 2 Trial of OcuRing™-K and GridFeed™ Opportunity in AI Data Center Power

GlobeNewswire report covering PRF Technologies Ltd. (PRFX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ChartMill • 3d ago

Postmarket Movers: After-Hours Gainers and Losers

After-hours movers: INOVIO jumped 283.0% and Glucotrack dropped 57.19%, among the largest postmarket gainers and losers.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PRFX Bull vs. Bear Conversation Board — What's Your Call at $0.73?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PRFX 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $0.66 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is PRFX (E • RQD 34/100) a Buy at $0.75?

Welcome to the PRFX (PRF Technologies Ltd.) Roar Pit. Current RQD Composite is 34/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $0.63 (-16.0%)

Spot @ $0.75

Pump the brakes on PRFX — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on PRFX, but look at what you are paying: current EV/EBITDA multiples with -30.0% gross margins. Unless PRF Technologies Ltd. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MA MacroHawk_NYC Verified K Arena Trader 🐂 BULLISH 🎯 Target: $0.93 (+24.0%)

Spot @ $0.75

PRFX cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on PRFX, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $0.75 (52-wk range $0.69 - $7.95), any beat on forward guidance forces shorts and underweight funds to chase.